XML 23 R8.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Cash Flows From Operating Activities:    
Net loss $ (25,653,000) $ (18,349,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation 671,000 552,000
Income tax benefit 0 (1,640,000)
In-process research and development impairment 1,325,000 0
Goodwill impairment 5,594,000 0
Change in fair value of contingent consideration 699,000 (660,000)
Payment of contingent consideration 0 (1,731,000)
Non - cash lease expense 452,000 388,000
Depreciation 137,000 135,000
Deferred research and development tax credit (888,000) 0
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 912,000 1,368,000
Deposits and other assets 1,000 (54,000)
Accounts payable 123,000 (157,000)
Accrued expenses 522,000 1,470,000
Accrued employee benefits (350,000) 104,000
Operating lease liability (482,000) (422,000)
Net Cash Used In Operating Activities (16,937,000) (18,996,000)
Cash Flows From Investing Activities:    
Purchases of property and equipment (1,000) (202,000)
Net Cash Used In Investing Activities (1,000) (202,000)
Cash Flows From Financing Activities:    
Payment of loans payable (67,000) (75,000)
Proceeds from issuance under at - the - market offering, net of issuance cost 3,603,000 2,219,000
Payment of contingent consideration 0 (1,519,000)
Proceeds from issuance Common Stock and Warrants offering, net of issuance costs 1,960,000 0
Net Cash Provided By Financing Activities 5,496,000 625,000
Effects of exchange rate changes on cash and cash equivalents (132,000) (33,000)
Net decrease in cash and cash equivalents and restricted cash (11,574,000) (18,606,000)
Cash and cash equivalents and restricted at the beginning of this period 23,279,000 41,885,000
Cash and cash equivalents and restricted cash at the end of this period 11,705,000 23,279,000
Reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheet    
Cash and cash equivalents 11,609,000 23,177,000
Restricted cash included in other long-term assets 96,000 102,000
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows 11,705,000 23,279,000
Supplemental non-cash investing and financing activities:    
Right of use assets obtained in exchange for lease liabilities 0 937,000
Series C Preferred Stock    
Supplemental non-cash investing and financing activities:    
Conversion of Preferred Stock to Common Shares 2,005,000 0
Series D Preferred Stock    
Supplemental non-cash investing and financing activities:    
Conversion of Preferred Stock to Common Shares $ 728,000 $ 0